The Impact of Androgen Receptor Expression on Breast Cancer Survival: a Retrospective Study and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Dec 11

PMID 24324816

Citations 62

Authors

Qing Qu

Yan Mao

Xiao-Chun Fei

Kun-Wei Shen

Affiliations

Soon will be listed here.

Abstract

Recent studies have highlighted the role of androgen receptor (AR) as a prognostic biomarker of breast cancer. However, its predictive role in disease free survival (DFS) and overall survival (OS) still remains inconclusive. The present study aimed to retrospectively investigate the association between AR and survival outcomes in breast cancer and also identify this association by a meta-analysis of published researches. Clinical data from 109 patients with breast cancer, who underwent surgery at Ruijin Hospital, Shanghai, were retrospectively analyzed for immunohistochemical AR expression measured by tissue microarray. For meta-analysis, articles available in Pubmed on the relationship between AR and breast cancer outcomes were included. Data obtained from both were combined and analyzed. Women with AR positive tumors in the retrospective study had a significantly better DFS (HR 0.24, 95% CI 0.07-0.88) and OS (HR 0.19, 95% CI 0.04-0.85) than women with AR negative ones. Meta-analysis showed that AR expression in breast tumors was an indicator of better DFS (HR 0.52, 95% CI 0.43-0.64). In subgroup analysis, AR could predict DFS outcome in estrogen receptor (ER) positive (HR 0.45, 95% CI 0.34-0.59), ER negative (HR 0.42, 95% CI 0.26-0.67), and triple negative breast cancer (HR 0.40, 95% CI 0.23-0.69). Moreover, in ER positive breast cancer patients, the expression of AR could predict better OS (HR 0.39, 95% CI 0.19-0.82). The present analysis indicated that AR expression was associated with lower risk of recurrence in patients with all breast cancer types and better OS in cases with ER positive.

Citing Articles

Hormone Signaling in Breast Development and Cancer.

Agnoletto A, Brisken C Adv Exp Med Biol. 2025; 1464():279-307.

PMID: 39821031 DOI: 10.1007/978-3-031-70875-6_15.

A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: Role of androgen receptor, JAK-STAT, and lineage plasticity.

Asemota S, Effah W, Holt J, Johnson D, Cripe L, Ponnusamy S Proc Natl Acad Sci U S A. 2024; 121(40):e2406837121.

PMID: 39312663 PMC: 11459127. DOI: 10.1073/pnas.2406837121.

Triple-negative breast cancer: from classical clinicopathological features to androgen receptor profile.

Prutianu I, Giusca S, Gafton B, Chifu M, Terinte C, Antonescu A Rom J Morphol Embryol. 2024; 65(2):209-216.

PMID: 39020535 PMC: 11384857. DOI: 10.47162/RJME.65.2.07.

Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis.

Wang X, Li X, Dong T, Yu W, Jia Z, Hou Y Int J Surg. 2024; 110(12):7962-7983.

PMID: 38857504 PMC: 11634138. DOI: 10.1097/JS9.0000000000001799.

The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification.

Weng L, Zhou J, Guo S, Xu N, Ma R Cancer Cell Int. 2024; 24(1):120.

PMID: 38555429 PMC: 10981301. DOI: 10.1186/s12935-024-03261-0.

References

Gonzalez L, Corte M, Vazquez J, Junquera S, Sanchez R, Alvarez A . Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer. 2008; 8:149. PMC: 2416360. DOI: 10.1186/1471-2407-8-149. View

Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax S, Weybora W . Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer. 2003; 98(4):703-11. DOI: 10.1002/cncr.11532. View

Luo X, Shi Y, Li Z, Jiang W . Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 2010; 29(6):585-90. DOI: 10.5732/cjc.009.10673. View

Peters K, Edwards S, Nair S, French J, Bailey P, Salkield K . Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events. BMC Cancer. 2012; 12:132. PMC: 3349557. DOI: 10.1186/1471-2407-12-132. View

Hu R, Dawood S, Holmes M, Collins L, Schnitt S, Cole K . Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011; 17(7):1867-74. PMC: 3076683. DOI: 10.1158/1078-0432.CCR-10-2021. View

Berry D, Cronin K, Plevritis S, Fryback D, Clarke L, Zelen M . Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353(17):1784-92. DOI: 10.1056/NEJMoa050518. View

Park S, Koo J, Kim M, Park H, Lee J, Kim S . Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol. 2011; 22(8):1755-62. DOI: 10.1093/annonc/mdq678. View

Loibl S, Muller B, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S . Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011; 130(2):477-87. DOI: 10.1007/s10549-011-1715-8. View

Soiland H, Korner H, Skaland I, Janssen E, Gudlaugsson E, Varhaug J . Prognostic relevance of androgen receptor detection in operable breast cancer. J Surg Oncol. 2008; 98(7):551-8. DOI: 10.1002/jso.21156. View

10.

Kuenen-Boumeester V, van der Kwast T, Claassen C, Look M, Liem G, Klijn J . The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer. 1996; 32A(9):1560-5. DOI: 10.1016/0959-8049(96)00112-8. View

11.

Schippinger W, Regitnig P, Dandachi N, Wernecke K, Bauernhofer T, Samonigg H . Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch. 2006; 449(1):24-30. DOI: 10.1007/s00428-006-0213-6. View

12.

Mrklic I, Pogorelic Z, capkun V, Tomic S . Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem. 2012; 115(4):344-8. DOI: 10.1016/j.acthis.2012.09.006. View

13.

Naderi A, Chia K, Liu J . Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011; 13(2):R36. PMC: 3219199. DOI: 10.1186/bcr2858. View

14.

Park S, Park H, Koo J, Yang W, Kim S, Park B . Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Res Treat. 2012; 133(1):311-20. DOI: 10.1007/s10549-011-1950-z. View

15.

He J, Peng R, Yuan Z, Wang S, Peng J, Lin G . Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2011; 29(2):406-10. DOI: 10.1007/s12032-011-9832-0. View

16.

. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

17.

Tang D, Xu S, Zhang Q, Zhao W . The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol. 2011; 29(2):526-33. DOI: 10.1007/s12032-011-9948-2. View

18.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

19.

Castellano I, Allia E, Accortanzo V, Vandone A, Chiusa L, Arisio R . Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010; 124(3):607-17. DOI: 10.1007/s10549-010-0761-y. View

20.

Peters A, Ingman W, Tilley W, Butler L . Differential effects of exogenous androgen and an androgen receptor antagonist in the peri- and postpubertal murine mammary gland. Endocrinology. 2011; 152(10):3728-37. DOI: 10.1210/en.2011-1133. View